US Bioservices has Pfizer’s XALKORI in stock – now FDA approved to treat metastatic non-small cell lung cancer

July 11, 2016

The U.S. Food and Drug Administration recently approved the expanded use of Pfizer’s XALKORI (crizotinib) for the treatment of metastatic non-small cell lung cancer (NSCLC), when tumors have an ROS-1 gene alteration. The FDA also granted XALKORI breakthrough therapy designation and priority review status.